Physician profile
Brian White
NPI 1124039649
$3,364.09
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,077 · 2020: $770 · 2021: $581 · 2022: $711 · 2023: $226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $225.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $615.20 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $591.51 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $494.14 | 2019-2023 | Stiolto Respimat, Spiriva Respimat |
| Genzyme Corporation | $161.25 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $147.93 | 2019-2023 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $142.44 | 2019-2023 | Opsumit |
| Janssen Pharmaceuticals, INC | $137.25 | 2020-2022 | |
| Mallinckrodt Hospital Products INC. | $122.73 | 2020-2022 | |
| Radius Health, INC. | $97.77 | 2022 | |
| Genentech USA, INC. | $97.10 | 2019 | |
| Pfizer INC. | $83.15 | 2019 | |
| United Therapeutics Corporation | $75.34 | 2021-2023 | Tyvaso, Orenitram |
| Novo Nordisk INC | $63.18 | 2021 | |
| Novartis Pharmaceuticals Corporation | $52.00 | 2019-2020 | |
| Electromed, INC. | $50.32 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $48.93 | 2019-2020 | |
| Amgen INC. | $46.30 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $40.33 | 2022 | |
| Fisher & Paykel Healthcare INC | $36.04 | 2019 | |
| Shire North American Group INC | $34.66 | 2019 | |
| Shionogi INC | $34.57 | 2022 | |
| Jazz Pharmaceuticals INC. | $34.54 | 2019-2021 | |
| Astellas Pharma US INC | $30.06 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $27.16 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.00 | 2020 | |
| Idorsia Pharmaceuticals US INC | $17.44 | 2023 | Quviviq |
| Sunovion Pharmaceuticals INC. | $16.69 | 2020 | |
| Baxter Healthcare | $15.98 | 2023 | Hillrom - Life 2000 Ventilation System |
| Pulmonx Corporation | $15.60 | 2019 | |
| Philips North America LLC | $14.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.